Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Brain Pathology (Zurich, Switzerland)|March 23, 2005
Genes associated with fast glioma cell migration in vitro and in vivoLars Tatenhorst, Sylvia Püttmann, Volker Senner, et al.
Journal of Neuropathology and Experimental Neurology|April 2, 2004
Regulators of G-protein signaling 3 and 4 (RGS3, RGS4) are associated with glioma cell motilityLars Tatenhorst, Volker Senner, Sylvia Püttmann, et al.
Neuromolecular Medicine|June 18, 2017
Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of Alpha-Synuclein AggregationEleonora Carboni, Lars Tatenhorst, Lars Tönges, et al.
Scientific Reports|February 29, 2024
Glypican-4 serum levels are associated with cognitive dysfunction and vascular risk factors in Parkinson's diseaseLars Tatenhorst, Fabian Maass, Hannah Paul, et al.
Journal of Cellular Physiology|September 25, 2004
Functional measurement of local proteolytic activity in living cells of invasive and non-invasive tumorsThomas Ludwig, Sylvia Püttmann, Helga Bertram, et al.
Acta Neuropathologica|January 20, 2004
Glioblastoma cells release factors that disrupt blood-brain barrier featuresStefan W Schneider, Thomas Ludwig, Lars Tatenhorst, et al.
Journal of Neurochemistry|May 22, 2009
PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma modelsAlessio Papi, Lars Tatenhorst, Dick Terwel, et al.
Pharmacology & Therapeutics|April 6, 2018
ROCK inhibition in models of neurodegeneration and its potential for clinical translationJan Christoph Koch, Lars Tatenhorst, Anna-Elisa Roser, et al.
Journal of Neuropathology and Experimental Neurology|July 9, 2014
Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson diseaseLars Tatenhorst, Lars Tönges, Kim-Ann Saal, et al.
Pageof 4